Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2022 | The future of CAR-T therapy: earlier use, new indications, & improved manufacturing

Christian Buchholz, PhD, Paul-Ehrlich-Institut, Langen, Germany, discusses advances in chimeric antigen receptor T-cell (CAR-T) therapy. Originally approved in B-cell precursor acute lymphoblastic leukemia (B-ALL), new CAR-T approaches are now being developed for a wider range of indications including other lymphoma subtypes and multiple myeloma. In addition, whilst CAR-Ts have only been approved in the third-line setting in lymphoma, there is an increasing body of evidence suggesting that these cellular therapies might be beneficial in earlier lines of treatment. In parallel, Dr Buchholz explains that companies are working on decreasing CAR-T manufacturing costs, thus making this treatment available for a larger number of patients. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.